Glioblastoma Genomics: A Very Complicated Story
Main Article Content
ABSTRACT
Glioblastoma is a deadly disease that has not shown improvement despite the development of new diagnostic tools and innovative targeted therapies. This grim outcome is mainly related to a complex intra- and inter-individual heterogeneity resulting from severe genetic instability. Understanding glioblastoma biology may establish a foundation to improve prophylaxis, early diagnosis, prognosis, and treatment prediction, thus leading to a better outcome. Recent advances in technologies such as genomics, epigenomics, transcriptomics, and proteomics have led to unprecedented discoveries of potential prognostic and predictive markers. Several of these biomarkers are in deep need of validation to be used in clinical routine. In this chapter, we will discuss the most accomplished recent advances in the genomics of glioblastoma and insight into personalized medicine using validated, and not yet validated, biomarkers that may have great potential to improve patients’ outcomes.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.